CoChat
Sign Up
Cited by 235Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2

Zukin, Mauro, Barrios, Carlos H., Rodrigues Pereira, Jose, De Albuquerque Ribeiro, Ronaldo, de Mendonça Beato, Carlos Augusto, do Nascimento, Yeni Neron, Murad, Andre, Franke, Fabio A., Precivale, Maristela, de Lima Araujo, Luiz Henrique, Da Rocha Baldotto, Clarissa Serodio, Vieira, Fernando Meton, Small, Isabele A., Ferreira, Carlos G., Lilenbaum, Rogerio C.·2013·Journal of Clinical Oncology
DOI 10.1200/jco.2012.48.1911
Open this paper in CoChat — free account

Abstract

PURPOSE: To compare single-agent pemetrexed (P) versus the combination of carboplatin and pemetrexed (CP) in first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC) with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2. PATIENTS AND METHODS: In a multicenter phase III randomized trial, patients with advanced NSCLC, ECOG PS of 2, any histology at first and later amended to nonsquamous only, no prior chemotherapy, and adequate organ function were randomly assigned to P alone (500 mg/m(2)) or CP (area under the curve of 5 and 500 mg/m(2), respectively) administered every 3 weeks for a total of four cycles. The primary end point was overall survival (OS). RESULTS: A total of 205 eligible patients were enrolled from eight centers in Brazil and one in the United States from April 2008 to July 2011. The response rates were 10.3% for P and 23.8% for CP (P = .032). In the intent-to-treat population, the median PFS was 2.8 months for P and 5.8 months for CP (hazard ratio [HR], 0.46; 95% CI, 0.35 to 0.63; P < .001), and the median OS was 5.3 months for P and 9.3 months for CP (HR, 0.62; 95% CI, 0.46 to 0.83; P = .001). One-year survival rates were 21.9% and 40.1%, respectively. Similar results were seen when patients with squamous disease were excluded from the analysis. Anemia (grade 3, 3.9%; grade 4, 11.7%) and neutropenia (grade 3, 1%; grade 4, 6.8%) were more frequent with CP. There were four treatment-related deaths in the CP arm. CONCLUSION: Combination chemotherapy with CP significantly improves survival in patients with advanced NSCLC and ECOG PS of 2.

Overview

Integrity signals

Registry

Crossref · 10.1200/jco.2012.48.1911

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 7 references

Cited by

Sorted by citations

Items 201–235 of 235

Related

See all

Metadata

Authors
Zukin, M., Barrios, C. H., Rodrigues Pereira, J., De Albuquerque Ribeiro, R., de Mendonça Beato, C. A., do Nascimento, Y. N., Murad, A., Franke, F. A., Precivale, M., de Lima Araujo, L. H., Da Rocha Baldotto, C. S., Vieira, F. M., Small, I. A., Ferreira, C. G., & Lilenbaum, R. C.
Affiliations
  • Hospital Haroldo Juaçaba (BR)
  • Mauro Zukin, Luiz Henrique de Lima Araujo, Clarissa Serodio Da Rocha Baldotto, Fernando Meton Vieira, Isabele A. Small, and Carlos G. Ferreira, Instituto Nacional do Cancer, Rio de Janeiro; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre; Jose Rodrigues Pereira, Instituto do Cancer Arnaldo Vieira Carvalho; Maristela Precivale, PGS Medical Statistics, Sao Paulo; Ronaldo De Albuquerque Ribeiro, Instituto do Cancer do Ceara, Fortaleza; Carlos Augusto de Mendonça Beato,...
ORCID
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
2013-08-10
Volume
31
Issue
23
Pages
2849-2853
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
DOI
10.1200/jco.2012.48.1911
OpenAlex
W2097268198
Cited by
235
References
7
Citations by year
2026: 2 · 2025: 11 · 2024: 8 · 2023: 12 · 2022: 16 · 2021: 14 · 2020: 20 · 2019: 20 · 2018: 26 · 2017: 17 · 2016: 25 · 2015: 26 · 2014: 28 · 2013: 9
FWCI
23.87
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
non-small cell lung cancer, pemetrexed, carboplatin, combination chemotherapy, first-line therapy, overall survival, progression-free survival, anemia, neutropenia, non-relapse mortality
MeSH terms
Pemetrexed, Adult, Aged, Aged, 80 and over, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Glutamates, Guanine, Humans, Lung Neoplasms, Male, Middle Aged, Prospective Studies, Survival Rate, Carboplatin, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review